FlowMetric Life Sciences announced that it has launched its COVID-19 antibody test, an advanced, multiplexed serology assay.

The diagnostic can differentiate between infections caused by virus exposure and infections caused by vaccine response, the company said, adding that the test holds a specificity and sensitivity rate greater than 99 percent. The company is offering the test at its high-complexity laboratory, which can process more than 1,000 samples daily and provides results in one to two days.

“The applications of this [test] are ideal for companies working on vaccine development or COVID-19-related therapeutics,” said FlowMetric founder and CEO Renold Capocasale.